FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases

Clinical Cancer Research

Volumn 9, Issue 12, 2003, Pages 4483-4493

  Yao, Qing ^a   Nishiuchi, Ritsuo ^a   Li, Quanzhi ^a   Kumar, Ashish R ^a   Hudson, Wendy A ^a   Kersey, John H ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; CHAPERONE; FLT3 LIGAND; GELDANAMYCIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HERBIMYCIN A; HYBRID PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; MLL AF4 FUSION PROTEIN; PHOSPHOTRANSFERASE; PROTEIN KINASE B; PROTEIN P23; RAF PROTEIN; SIGNAL TRANSDUCTION ASSOCIATED KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL SPECIFICITY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME STABILITY; EVALUATION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INHIBITION KINETICS; LEUKEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TANDEM REPEAT; WILD TYPE;

APOPTOSIS; BENZOQUINONES; CELL CYCLE; DOWN-REGULATION; ENZYME INHIBITORS; ENZYME STABILITY; FMS-LIKE TYROSINE KINASE 3; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; LEUKEMIA, MYELOID; MOLECULAR CHAPERONES; MYELOID-LYMPHOID LEUKEMIA PROTEIN; ONCOGENE PROTEINS, FUSION; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; PRECIPITIN TESTS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-RAF; PYRIDINOLCARBAMATE; RECEPTOR PROTEIN-TYROSINE KINASES; RIFABUTIN; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0141925960     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Blagosklonny, M. V., Fojo, T., Bhalla, K. N., Kim, J. S., Trepel, J. B., Figg, W. D., Rivera, Y., and Neckers, L. M. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia (Baltimore), 15: 1537-1543, 2001.
2. Blagosklonny, M. V. Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia (Baltimore), 16: 455-462, 2002.
3. Pratt, W. B., and Toft, D. O. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med., 22: 111-133, 2003.
4. Stebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., and Pavletich, N. P. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell, 89: 239-250, 1997.
5. Schulte, T. W., and Neckers, L. M. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother. Pharmacol., 42: 273-279, 1998.
6. Whitesell, L., and Cook, P. Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells. Mol. Endocrinol., 10: 705-712, 1996.
7. Dasgupta, G., and Momand, J. Geldanamycin prevents nuclear translocation of mutant p53. Exp. Cell Res., 237: 29-37, 1997.
8. Tikhomirov, O., and Carpenter, G. Geldanamycin induces ErbB-2 degradation by proteolytic fragmentation. J. Biol. Chem., 275: 26625-26631, 2000.
9. Ayton, P. M., and Cleary, M. L. Molecular mechanisms of leuke-mogenesis mediated by MLL fusion proteins. Oncogene, 20: 5695-5707, 2001.
10. Kersey, J. H., Wang, D., and Oberto, M. Resistance of t(4;11) (MLL-AF4 fusion gene) leukemias to stress-induced cell death: possible mechanism for extensive extramedullary accumulation of cells and poor prognosis. Leukemia (Baltimore), 12: 1561-1564, 1998.
11. Armstrong, S. A., Staunton, J. E., Silverman, L. B., Pieters, R., den Boer, M. L., Minden, M. D., Sallan, S. E., Lander, E. S., Golub, T. R., and Korsmeyer, S. J. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat. Genet., 30: 41-47, 2002.
12. Christiansen, D. H., and Pedersen-Bjergaard, J. Internal tandem duplications of the FLT3 and MLL genes are mainly observed in atypical cases of therapy-related acute myeloid leukemia with a normal karyotype and are unrelated to type of previous therapy. Leukemia (Baltimore), 15: 1848-1851, 2001.
13. Wilson, R. H., Takimoto, C. H., Agnew, E. B., Morrison, G., Grollman, F., Thomas, R. R., Saif, M. W., Hopkins, J., Allerga, C., Grochow, L., Szabo, E., Hamilton, J. M., Brain, P., Monahan, B. P., Neckers, L., and Grem, J. L. Demethoxygeldanamycin (AGG) in adult patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol., 82a, 2001.
14. Munster, P. N., Tong, W., Schwartz, L., Larson, S., Kenneson, K., De La Cruz, A., Rosen, N., and Scher, H. Phase 1 trial of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) in patients (pts) with advanced solid malignancies. Proc. Am. Soc. Clin. Oncol., 83a, 2001.
15. Banerji, U., O'Donnell, A., Scurr, M., Benson, C., Hanwell, J., Clark, S., Raynaud, F., Turner, A., Walton, M., Workman, P., and Judson, I. Phase 1 trial of the heat shock protein 90 (HSP90) inhibitor 17-allylamino 17-demethoxygeldanamycin 17aag). Pharmacokinetic (PK) profile and pharmacodynamic (PD) endpoints. Proc. Am. Soc. Clin. Oncol., 82a, 2001.
16. Yamamoto, Y., Kiyoi, H., Nakano, Y., Suzuki, R., Kodera, Y., Miyawaki, S., Asou, N., Kuriyama, K., Yagasaki, F., Shimazaki, C., Akiyama, H., Saito, K., Nishimura, M., Motoji, T., Shinagawa, K., Takeshita, A., Saito, H., Ueda, R., Ohno, R., and Naoe, T. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood, 97: 2434-2439, 2001.
17. Xu, F., Taki, T., Yang, H. W., Hanada, R., Hongo, T., Ohnishi, H., Kobayashi, M., Bessho, F., Yanagisawa, M., and Hayashi, Y. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. Br. J. Haematol., 105: 155-162, 1999.
18. Clarke, P. A., Hostein, I., Banerji, U., Stefano, F. D., Maloney, A., Walton, M., Judson, I., and Workman, P. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene, 19: 4125-4133, 2000.
19. Hostein, I., Robertson, D., DiStefano, F., Workman, P., and Clarke, P. A. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res., 61: 4003-4009, 2001.
20. Minami, Y., Kiyoi, H., Yamamoto, Y., Yamamoto, K., Ueda, R., Saito, H., and Naoe, T. Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors. Leukemia (Baltimore), 16: 1535-1540, 2002.
21. Richter, K., and Buchner, J. Hsp90: chaperoning signal transduction. J. Cell. Physiol., 188: 281-290, 2001.
22. 165 promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood, 99: 2532-2540, 2002.
23. Tse, K. F., Novelli, E., Civin, C. I., Bohmer, F. D., and Small, D. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia (Baltimore), 15: 1001-1010, 2001.
24. Levis, M., Tse, K. F., Smith, B. D., Garrett, E., and Small, D. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood, 98: 885-887, 2001.
25. Levis, M., Allebach, J., Tse, K. F., Zheng, R., Baldwin, B. R., Smith, B. D., Jones-Bolin, S., Ruggeri, B., Dionne, C., and Small, D. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood, 99: 3885-3891, 2002.
26. Kelly, L. M., Yu, J., Boulton, C. L., Apatira, M., Li, J., Sullivan, C. M., Williams, I., Amaral, S. M., Curley, D. P., Ducols, N., Neuberg, D., Scarborough, R. M., Pandey, A., Hollenbach, S., Abe, K., Lokker, N. A., Gilliland, D. G., and Giese, N. A. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell, 1: 421-432, 2002.
27. Weisberg, E., Boulton, C., Kelly, L. M., Manley, P., Fabbro, D., Meyer, T., Gilliland, D. G., and Griffin, J. D. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell, 1: 433-443, 2002.
28. Yee, K. W., O'Farrell, A. M., Smolich, B. D., Cherrington, J. M., McMahon, G., Wait, C. L., McGreevey, L. S., Griffith, D. J., and Heinrich, M. C. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood, 100: 2941-2949, 2002.
29. Naoe, T., Kiyoe, H., Yamamoto, Y., Minami, Y., Yamamoto, K., Ueda, R., and Saito, H. FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy. Cancer Chemother. Pharmacol., 48 (Suppl. 1): S27-S30, 2001.
30. Stancato, L. F., Chow, Y. H., Hutchison, K. A., Perdew, G. H., Jove, R., and Pratt, W. B. Raf exists in a native heterocomplex with hsp90 and p50 that can be reconstituted in a cell-free system. J. Biol. Chem., 268: 21711-21716, 1993.
31. Sato, S., Fujita, N., and Tsuruo, T. Modulation of Akt kinase activity by binding to Hsp90. Proc. Natl. Acad. Sci. USA., 97: 10832-10837, 2000.
32. An, W. G., Schulte, T. W., and Neckers, L. M. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ., 11: 355-360, 2000.
33. Zhang, S., and Broxmeyer, H. E. Flt3 ligand induces tyrosine phosphorylation of gab1 and gab2 and their association with shp-2, grb2, and PI3 kinase. Biochem. Biophys. Res. Commun., 277: 195-199, 2000.
34. Srinivasa, S. P., and Doshi, P. D. Extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways cooperate in mediating cytokine-induced proliferation of a leukemic cell line. Leukemia (Baltimore), 16: 244-253, 2002.
35. Gilliland, D. G., and Griffin, J. D. Role of FLT3 in leukemia. Curr. Opin. Hematol., 9: 274-281, 2002.
36. Mizuki, M., Fenski, R., Halfter, H., Matsumura, I., Schmidt, R., Muller, C., Gruning, W., Kratz-Albers, K., Serve, S., Steur, C., Buchner, T., Kienast, J., Kanakura, Y., Berdel, W. E., and Serve, H. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood, 96: 3907-3914, 2000.
37. Mizuki, M., Schwable, J., Steur, C., Choudhary, C., Agrawal, S., Sargin, B., Steffen, B., Matsumura, I., Kanakura, Y., Bohmer, F. D., Muller-Tidow, C., Berdel, W. E., and Serve, H. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood, 101: 3164-3173, 2003.